NEW YORK, NY--(Marketwired - March 19, 2014) - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Erytech (EURONEXT: ERYP.PA), a biotechnology company developing innovative treatments for oncology, with three ongoing clinical trials for lead candidate GRASPA/ERY-ASP in patients with acute lymphoblastic leukemia (ALL). The product candidate is known as GRASPA in Europe and as ERY-ASP in the US and rest of the world. It is a pioneering approach for delivering cancer-fighting agents to patients by encapsulation in red blood cells (RBCs) to minimize unwanted side effects. GRASPA/ERY-ASP contains L-asparaginase, which is a potent anti-cancer agent that is not commonly used in adults due to a high rate of side effects in the population. The market for L-asparaginase is currently limited to pediatric patients, and a product with a more favorable safety profile has the potential to expand use into adults, seniors, and relapsed patients.
"Erytech is developing GRASPA as a potentially safe and effective therapy for patients with acute lymphoblastic leukemia, an indication with few good treatment options," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "This technology platform has the potential to deliver L-asparaginase, which is known to be active against pediatric ALL, in a way that is safe and efficacious for all patients."
Erytech is testing GRASPA in three ongoing clinical trials. A European Phase III trial in relapsed adults and children with acute lymphoblastic leukemia (ALL) is expected to be completed in the third quarter of 2014. A Phase I/II trial with adult ALL patients is ongoing in the US, and a European Phase IIb trial in elderly AML patients received a positive Data and Safety Monitoring Board review in November 2013. The Company is also planning a European Phase II clinical study to evaluate the efficacy of GRASPA administered concurrently with chemotherapy in second line pancreatic cancer. Patient enrollment is expected to begin in the second quarter of 2014, with data potentially available in 2015.
In a 41 page Initiation Report by LifeSci Advisors, we explain the development path and preclinical data for GRASPA/ERY-ASP. The report details Erytech's strategy to conduct clinical trials designed to show that the treatment is at least as effective as and safer than current L-asparaginase treatments. The trials may support European and US regulatory approval based on a bioequivalence regulatory route. We examine the landscape for currently available and developing treatments for ALL as well as other potential applications for Erytech's platform technology.
Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.